1. Introduction {#s0005}
===============

Antibiotics have been used since the 1940s to treat patients who have infectious diseases, and have significantly contributed in morbidity and mortality reduction from these infections ([@b0070]). When prescribing antibiotics, clinicians should necessarily take into account the correct diagnosis of the infection, potential risk of antibiotic resistance and existing resistance patterns, patient and drug characteristics, potential medication side effects, the difference between empiric and definitive antibiotic therapy, types of broad spectrum antibiotics and the switch to narrow spectrum ones, in addition to the costs of the prescribed antibiotics ([@b0050]).

Hospital-based programs have devoted the Antibiotic Stewardship Programs (ASPs) to improve and control antibiotics prescription and to optimize the quality of care of the infected patients. In 2014, all acute care hospitals were encouraged to conduct ASPs as recommended by Centers for Disease Control and prevention (CDC), an organization that is concerned in health issues in United States. The core elements of ASPs include: chief commitment, accountability, drug expertise, action, tracking, reporting and education ([@b0070]). Pharmacists play an important role in ASP, their responsibilities involve promoting the best utilization of antibiotics, decreasing the transference of infections and providing information about antibiotics for patients, health care professionals and the public ([@b0020], [@b0065]).

The CDC (2015) estimated that 30% of antibiotics prescriptions in hospitals are inappropriate or unnecessary. Accordingly, new guidelines were released by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). These guidelines indicate that preauthorization of broad spectrum antibiotics and reviewing it prospectively after two or three days of the treatment form the cornerstone of ASP, with the aim of ensuring that the right drug is prescribed for the right indication at the right time ([@b0045]). In Jordan, more than 50% of physicians prescribe antibiotics routinely for treatment of common cold symptoms. Approximately, 67% of adult Jordanians believe that antibiotics are necessary for the treatment of common cold and cough ([@b0080]). However, when these antibiotics are used in wrong way, they will give a little benefit, lead to bad consequences and expose the patient to the risk of adverse events such as C. difficile infections, disruption of normal flora, development of antibiotic-resistant infections which may lead to the development of more severe diseases and complications and increase the length of hospital stay, in addition to the increase in mortality rates and health care costs ([@b0040], [@b0055]).

The concept of antibiotic resistance and misuse has been investigated in earlier studies in Jordan. A study was conducted to determine the prevalence of resistance in gram negative bacteria due to antibiotic use for patients admitted to the ICU at Prince Hashem Hospital showed that Pseudomonas aeruginosa was the most resistant pathogen, and there was an increase in the rate of broad-spectrum antibiotics resistance such as amikacin and piperacillin/tazobactam ([@b0025]). Another study was carried out to evaluate the adherence to antibiotic prophylaxis guidelines in cardiac surgery department at Queen Alia Heart Institute (QAHI) reported non-adherence to guidelines of surgical prophylaxis and inappropriate antibiotics prescribing. The latter study highlighted the importance of clinical pharmacist involvement in the patient care process in order to improve the current antibiotics prescription and monitoring practice ([@b0015]).

Aim of the study {#s0010}
----------------

The aim of the study was to describe patterns of antibiotics prescription and adherence to guidelines of IV to oral antibiotic conversion in elderly patients visiting King Abdullah University Hospital (KAUH).

2. Methods {#s0015}
==========

2.1. Study settings and subjects {#s0020}
--------------------------------

The current cross-sectional study used a retrospective audit of inpatients who took IV antibiotics during the period from April 2017 through July 2017. The study was conducted in KAUH in Jordan, which is the largest hospital in the north of Jordan, serving about one million inhabitants from regions of Irbid, Mafraq, Ajloun and Jerash. It is also a teaching hospital that is linked to Jordan University of Science and Technology (JUST).

Inclusion and exclusion criteria were determined based on the IV to PO conversion rules. Patients were included if they were able to tolerate oral fluids and to absorb oral drugs sufficiently via oral, feeding or nasogastric tube route. Patients were excluded if they were found to match any of the following criteria according to (1) absorption status including: age less than 18 years, status of no oral intake (NPO), requested bowel rest for fistula, suffered from inflammatory bowel disease, pancreatitis, or abdominal surgeries, had active gastrointestinal bleeding, had malabsorption syndrome such as obstruction, suffered from persistent nausea, vomiting or diarrhea, had motility disorder of the gastrointestinal system, shad hort bowel syndrome or gastroparesis. (2) Physical inability including: patients with risk of aspiration or inability to swallow unless the patient was able to take drugs via feeding tube, patients undergoing nasogastric (NG) suctioning continuously or had NG output more than 150 ml ≥2 times in a 24-h period, continuous tube feeds and patients who refuse to take oral medication. (3) Disease severity including Intensive care unit vasopressor dependents or those who are unstable hemodynamically, patients with decreased level of consciousness or seizures, immunocompromised patients, patients who suffer from life-threatening infection or serious disease state which needs full duration of IV drug such as central nervous system infection, bacteremia, osteomyelitis, endocarditis, septic arthritis, endophthalmitis, fungaemia or orbital cellulitis.

2.2. Data collection {#s0025}
--------------------

By referring to information technology department in KAUH, a list of inpatients who took IV antibiotics in the period from April 2017 through July 2017 was obtained. A list of IV antibiotics that were used in the hospital was obtained from pharmacy department. Data were collected using data collection form which includes patient's file number, age, gender, height, weight, vital signs, WBC count, serum creatinine, type and the dosage regimen of the prescribed IV antibiotics in addition to the full medical history. Following data collection, the eligibility of each patient for conversion from IV to oral route based on SHEA criteria was evaluated.

2.3. Clinical criteria for IV to oral conversion {#s0030}
------------------------------------------------

IV to PO antibiotics conversion is warranted if the patient: received \>24 h of ordered IV antibiotics, showed an improving symptoms, had a confirmed clinical stability with the following parameters: negative cultures of blood for ≥48 h, stable or normal white blood cell (WBC) count and was afebrile i.e. temperature \<100.4 °F (38 °C) for \>24 h.

2.4. Ethical approval {#s0035}
---------------------

After being approved by the research committee at the Faculty of Pharmacy in JUST, the study was approved by the Institutional Review Board (approval number 22-104-2017) at KAUH.

2.5. Statistical analysis {#s0040}
-------------------------

Simple descriptive statistics including percentages and means were used to describe the demographic and clinical characteristics of the study participants in addition to patterns of antibiotics prescription.

3. Results {#s0045}
==========

During the study period, 11,998 patients were admitted to all wards of hospital. By excluding ineligible patients, 80 patients were found to be eligible for inclusion in this study. Half of the participants (50%) were female, (40%) aged more than 65 years (elderly), and the mean age was 57.2 (SD = 19.93). Majority of the study participants (70%) were overweight (35%) and obese (35%). Regarding kidney function, 23.8% of the study participants had normal kidney function (CrCl \> 90 ml/min), while the remaining had declined renal function with 5% of the participants were found to have end stage kidney failure without dialysis (CrCl \< 15 ml/min). [Table 1](#t0005){ref-type="table"} illustrates demographic and clinical characteristics of the study participants.Table 1Characteristics of the study participants (n = 80).Parametern (%)*Age*\<65 years48(60)≥65 years32 (40)  *Gender*Female40 (50)Male40 (50)  *Body Mass Index*Under weight (\<18.5)2 (2.5)Normal (18.5--24.99)21 (26.3)Overweight (25--29.99)28 (35.0)Obese (≥30)28 (35.0)  *Creatinine clearance*CrCl \> 90 ml/min (stage 1)19 (23.8)CrCl (60--89) ml/min (stage 2)17 (21.3)CrCl (30--59) ml/min (stage 3)29 (38.8)CrCl (15--29) ml/min (stage 4)8 (10.0)CrCl \< 15 ml/min (stage 5)4 (5.0)[^1]

[Fig. 1](#f0005){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}, respectively describe the types of infections and antibiotics prescribed for the study sample. The most commonly prevalent infection was urinary tract infection (53.75%), followed by respiratory tract infection (23.75%), diabetic foot infection cases (8.75%), surgical site infection cases (6.25%) and cellulitis (3.75%). However, there was one pregnant case that had follicular tonsillitis, one postpartum female, and one case had spine osteomyelitis. A total of 110 antibiotics were dispensed for 80 patients, imipenem/cilastatin was the most commonly prescribed antibiotic (41.25%) followed by cephalosporines which were where prescribed for 27.50% of the participants. The most commonly prescribed antibiotic in UTI patients was imipenem/cilastatin (58.14%) followed by ceftriaxone (37.21%), while the most commonly prescribed antibiotic for respiratory tract infection was levofloxacin (78.95%) followed by piperacillin/tazobactam (36.84%). Findings revealed that 47.5% of the patients were prescribed IV antibiotics although they were eligible for IV to oral conversion, and 36.25% of the patients were prescribed antibiotics without renal dose adjustments. [Table 3](#t0015){ref-type="table"} provides illustrations for the need to shift from IV to oral dosage forms, while [Table 4](#t0020){ref-type="table"} provides illustrations for inability to shift to oral dosage forms.Fig. 1Types of infection affected study patients.Table 2Percentage of prescribed antibiotic per class (n = 80).Antibiotic classn (%)*Carbapenems*Imipenem/Cilastatin33 (41.3)Meropenem3 (3.8)Ertapenem2 (2.5)  *Cephalosporines*Ceftriaxone20 (25.0)Cefuroxime2 (2.5)  *Extended spectrum penicillin/Beta lactamase inhibitor*Piperacillin/Tazobactam16 (20.0)  *Quinolones*Levofloxacin15 (18.8)  *Nitroimidazoles*Metronidazole9 (11.3)  *Glycopeptides*Teicoplanin4 (5.0)Vancomycin3 (3.8)  *Aminoglycosides*Amikacin1 (1.3)Gentamycin1 (1.3)  *Polymyxin E*Colistin2 (2.5)Table 3Illustrations and justifications for the need to shift from IV to oral dosage forms.CaseAntibioticsJustification for conversion to oralEvaluation of elevated serum creatinineCeftriaxone 2 g IV q 24 h for 8 daysUA show no pyuria or bacteriuria at admission, Urine culture is negative, vitals are within normal, no previous admission or at home of taking ABX, so no need for IV ABXSuspected uncomplicated pyelonephritisCeftriaxone 2 g IV q 24 h for 9 daysThe patient had stable vitals without nausea or vomiting, afebrile, had history of prior hospitalization 4 days before discharged on ciprofloxacin, as a result UC was negative, can be treated as outpatient with trimethoprim/sulfamethoxazole for 14 days or given a short course of ceftriaxone, then converted to oral ABXSuspected uncomplicated pyelonephritisCeftriaxone 2 g IV q 24 h for one dayPatient had flank pain, was afebrile, can tolerate oral intake, UA does not show pyuria, had not previous hospitalization or ABX intake, so the patient can be given ciprofloxacin or trimethoprim/sulfamethoxazole and no justification to give IV ceftriaxoneComplicated cystitisImipenem-cilastatin 500 mg IV q 8 h for 4 daysPatient admitted through outpatient clinic complain of dysuria, was clinically well, afebrile, with no previous ABX or admissions, UA showed abundant WBC, UC showed only heavy bacteria without sensitivity, can be treated as outpatient with oral ciprofloxacinComplicated cystitisCeftriaxone 2 g IV q 24 h for 2 daysPatient had dysuria, UA showed WBC (0--2), no bacterial growth, had previous ABX intake before 20 days of ciprofloxacin\
Patient can be treated with oral trimethoprim/sulfamethoxazolePuerperal infections (post-partum infection 10 days after deliveryMetronidazole 500 mg IV q 12 h, ceftriaxone 2 g IV q 24 h, gentamicin 80 mg IV q 12 h for 2 daysAs Patient was afebrile, had normal WBC, UA showed mixed growth, vaginal swap was normal, patient can be converted to and treated with oral ABX (clindamycin)Occipital pain for two months, malignant otitis externa, had left ear greenish dischargePiperacillin tazobactam 4.5 g IV q 6 h, teicoplanin 200 mg IV once daily for 5 daysCulture of pus after three days showed no growth, and patient was vitally stable, so can be converted to oral ABX (ex, ciprofloxacin)Complicated cystitisImipenem/cilastatin 500 mg IV q 6 h for 4 daysPatient was afebrile and vitally stable, had generalized abdominal pain, admitted due to positive UC without sensitivity, can be converted to oral ABX or started with it (oral ciprofloxacin), no previous ABX given at homeESBL negative E. coli, uncomplicated pyelonephritisImipenem/cilastatin 250 mg IV q 6 h for 7 daysUC showed ESBL negative UTI, sensitive to ceftriaxone, trimethoprim, nitrofurantoin, so can be converted to oral ABX as its sensitive to oral one, or can be given ciprofloxacinUncomplicated pyelonephritisImipenem/cilastatin 500 mg IV q 6 h for 2 days, ceftriaxone 2 g IV q 24 h for 7 daysUA show abundant bacteria, UC showed heavy bacteria without sensitivity, although it was repeated 3 times with the same result (heavy bacterial growth), afebrile during hospitalization, can be converted to oral ciprofloxacinESBL negative E. coli, complicated cystitisCeftriaxone 2 g IV q 24 h for 4 days.Patient admitted for evaluation due to suspected UTI, culture sensitivity showed ESBL negative sensitive to norfloxacin, ciprofloxacin, levofloxacin, cefazolin, and the patient was afebrile during hospitalization, can be converted to oral ABX, or given oral ciprofloxacin from beginningAsthma exacerbationLevofloxacin 500 mg IV q 24 h for 7 days.Patient was afebrile, normal WBC, chest x ray showed left sided haziness, SO~2~ at room air 95.8% upon admission, can be converted to oral levofloxacinComplicated cystitisCeftriaxone 2 g IV q 24 h for 17 daysElderly patient admitted to psychiatry unit, UA showed heavy with urinary symptoms, afebrile, after week of admission, UC showed no growth, patient can be converted to oral ABX once the culture was negativeSuspicion of lower respiratory tract infectionCeftriaxone 1 g IV twice daily for 3 daysPatient had history of sore throat before admission and took ABX (azithromycin),vitals were normal, WBC normal, can be converted to oral ABX such as levofloxacinESBL negative UTI, complicated pyelonephritisImipenem/cilastatin 500 mg IV q 6 h for 7 daysUC showed ESBL −ve, sensitive to nitrofurantoin and ertapenem, no history of nausea or vomiting, afebrile, normal WBC, however can be treated with short course IV ABX, and then converted to oral ABXChest infectionLevofloxacin 500 mg IV once daily for one dayAs the patient afebrile with normal WBC, can be converted from the beginning to oral levofloxacinChest infectionLevofloxacin 500 mg IV once daily for 8 daysPatient admitted due to SOB, chest infection vs Pulmonary Embolism, afebrile, normal WBC good O~2~ on room air, so can be converted to oral levofloxacinPneumonia, patient had history of asthmaLevofloxacin 500 mg IV once daily, piperacillin/tazobactam 4.5 g IV q 6 h for 3 daysVitals normal, WBC normal, can be treated as outpatient with oral levofloxacinAsthma exacerbation, patient had asthma, not compliant to her medicationsLevofloxacin 500 mg IV once daily for 5 daysPatient had normal vitals, not compliant to asthma medication, can be converted to oral levofloxacinSOB, decompensated HFPiperacillin/tazobactam 4.5 g IV q 6 h, levofloxacin 500 mg IV once daily for 2 daysAs patient had decompensated heart failure, no justification for ABX, however can be converted to oral levofloxacinSOB for 2 days PTA, patient admitted before one day to hospital due to decompensated HF, he had HF, COPD, CABGLevofloxacin 250 mg IV once daily for 6 daysVitals and WBC were normal during admission, can be given oral levofloxacin. However, his symptoms may be from decompensated HFAsthma exacerbationLevofloxacin 500 mg IV once daily for 22 daysPatient's vitals and WBC were normal, however can be converted to oral levofloxacin, although the use of ABX in asthma exacerbation is controversialCellulitis, right leg cellulitisMetronidazole 500 mg IV q 8 h, cefuroxime 750 mg IV three times daily for 4 daysNo discharge or fever, normal WBC, can be treated as outpatient with oral cefuroxime and oral metronidazoleProstatitisImipenem/cilastatin 500 mg IV q 6 h for 4 daysOn the second day of admission patient was afebrile (also vitals upon admission was normal without fever, fever was documented only in the home), UA was normal on 24/3, UC later showed no growth, can be converted to ciprofloxacin on the second dayDiabetic ulcer infectionTeicoplanin 400 mg IV once daily for 8 daysPus culture result in third day of admission showed MRSA sensitive to linezolid, vancomycin, teicoplanin, moxifloxacin, so can be converted to oral ABX as patient was afebrile and WBC was normalPost orchidopexy for evaluationCefuroxime 750 mg IV q 8 h for 2 daysPatient has no urinary symptoms, vitally stable, admitted post orchidopexy for evaluation, can be converted to oral cefuroximeComplicated cystitisPiperacillin-tazobactam 2.25 g IV q 6 h for 5 daysPatient had no fever during and at admission, UA showed abundant bacteria, UC on third day showed no growth, WBC normal, no previous admissions or ABX given, can be converted to oral ciprofloxacinChest infectionLevofloxacin 500 mg IV q 24 h for 6 daysPatient's vitals were stable, no fever, no increase in WBC, he had right lung mass, can be converted to levofloxacin orallyChest infectionLevofloxacin 500 mg IV q 24 h for 2 daysPatient had stable vitals, and normal WBC, can be converted to oral levofloxacin at admissionDiabetic foot infectionImipenem/cilastatin 500 mg IV q 6 h for 6 days, piperacillin tazobactam 4.5 g IV q 6 h for 4 daysPus culture in third day of admission showed P. aeruginosa sensitive to ciprofloxacin, otherwise vitals stable, WBC normal, can be converted to oral ciprofloxacinFor cystoscopyCeftriaxone 2 g IV once daily for 4 daysUA normal, UC normal, can be converted to oral ciprofloxacin, however cystoscopy as procedure need one dose of oral ciprofloxacinFor cystoscopyCeftriaxone 2 g IV q 24 h for 4 daysUA normal, UC normal, can be converted to oral ciprofloxacin, however cystoscopy as procedure need one dose of oral ciprofloxacinProstatitisCeftriaxone 2 g IV q 24 h for 3 daysPatient was vitally stable, WBC normal, UA at admission free of WBC and bacteria, UC free, can be converted at admission to ciprofloxacin or trimethoprim/sulfamethoxazolePneumoniaPiperacillin/tazobactam 4.5 g IV q 6 h, levofloxacin 500 mg IV once daily for 8 daysOn fourth day of admission, patient was febrile, then after that there was no fever at all, WBC was normal, patient can be converted to oral levofloxacin on day 6Kidney stoneCeftriaxone 2 g IV daily for 5 daysAt admission the UA was normal no pyuria or bacteriuria, patient vitally stable with other normal laboratory result, patient had only stone, can be converted to oral ciprofloxacin, however no justification for giving IV ABXThoracoscopy, patient has right lower chest pain for one month admitted for thoracoscopy (right lung cystImipenem/cilastatin 500 mg IV q 6 h for 9 daysAs the patient was vitally stable, afebrile during hospitalization, the chest pain was due to cyst, can be given oral levofloxacin, however no justification for IV ABXSurgical site infection, after left hip replacementVancomycin1g IV q12h for 10 daysPus culture on third day showed no pathogen, vitally stable without fever, normal WBC, can be converted to oral vancomycinSurgical site infection, after left total knee replacementVancomycin 1 g IV q 12 h for 11 days, piperacillin/tazobactam 4.5 g IV q 6 h for 4 daysPus culture on third day showed staph epidermis sensitive to moxifloxacin, linezolid, clindamycin, teicoplanin, rifampin, vancomycin, as the patient was stable, normal WBC, can be converted to oral ABX[^2]Table 4Illustrations and justifications for inability to shift from IV to oral dosage forms.CaseAntibioticsJustification for inability of oral conversionDiabetic foot infectionMetronidazole 500 mg IV q 12 h, piperacillin tazobactam 4.5 g IV q 6 h for 6 daysSever infection for amputationMDR UTI, complicated cystitisColistimethate sodium 1 million units q 8 h, amikacin250 mg once daily for 4 daysMDR P. aeruginosa sensitive only to IV amikacin and colistinMDR UTI, complicated pyelonephritisPiperacillin/tazobactam 4.5 g IV q 6 h for 3 days, metronidazole 500 mg IV q 8 h, meropenem 1 g IV q 8 h for 7 daysMDR organism sensitive only to IV meropenem and amikacinESBL + UTI, complicated cystitisCeftriaxone 2 g IV q 24 h for 3 days, imipenem/cilastatin 500 mg IV q 6 h for 4 daysUC showed ESBL + UTI, should be treated with IV ABXSurgical site infection, surgical debridement after infection of femur after plate insertionImipenem/cilastatin 1 g IV q 6 h for 6 daysSever infectionSpine osteomyelitis, patient has a history of extrapulmonary TB and multiple admissionsImipenem/cilastatin500mg IV q6hours, teicoplanin400 mg IV q 24 h for 11 daysSerious infection should be treated with IV ABXSurgical site infection after right hemiarthroplastyImipenem/cilastatin 500 mg IV q 6 h, colistin 2 million units IV three times daily for 35 daysSever infection, culture showed MDR Acinetobacter sensitive only to colistinESBL + UTI, complicated cystitisImipenem/cilastatin 250 mg IV three times daily for 6 daysElderly patient had ESBL + klepsiella referred to hospital after a call for result of her UC done in outpatient clinic, sensitive to levofloxacin, ciprofloxacin, nitrofurantoin, ESBL +ve should be treated with IV carbapenemESBL + UTI, complicated cystitisErtapenem 1 g IV once daily for 3 daysESBL +ve should be treated with IV carbapenemChest pain, shortness of breath for 4 months duration, had left sided plural effusionPiperacillin/ tazobactam 4.5 g IV q 6 h for 7 days, levofloxacin 500 mg IV once daily for 10 daysPatient was clinically deteriorated and then became febrileESBL + UTI, complicated cystitisImipenem/cilastatin 250 mg IV twice daily for 12 daysESBL +ve should be treated with IV carbapenemESBL + UTI, complicated cystitisImipenem/cilastatin 250 mg IV twice daily for 7 daysESBL +ve should be treated with IV carbapenemESBL + UTI, complicated cystitisImipenem/cilastatin 250 mg IV twice daily for 4 daysESBL +ve should be treated with IV carbapenemTonsillitis, follicular tonsillitis, patient allergic to ceftriaxoneLevofloxacin 500 mg IV once daily, metronidazole 500 mg IV q 8 h for 2 daysSever infection and the patient had difficulty swallowing.Cellulitis of right hand and forearmTeicoplanin 400 mg IV q12hours for the first 2 days, 200 mg once daily for the next 3 days, piperacillin tazobactam 2.25 mg IV q 6 h for 5 daysPatient was clinically deteriorated and became febrileESBL + UTI, complicated cystitisImipenem/cilastatin 500 mg IV q 6 h for 3 days.ESBL +ve should be treated with IV carbapenemESBL + UTI, complicated cystitisImipenem/cilastatin 500 mg IV q 6 h for 4 daysESBL +ve should be treated with IV carbapenemESBL + UTI, complicated cystitisImipenem/cilastatin 250 mg IV q 8 h for the first 2 days, and 250 mg IV q 6 h for the next 2 daysESBL +ve should be treated with IV carbapenemEpididymitis, scrotal pain of mild to moderate severity without urinary symptomsCeftriaxone 2 g IV once daily for 2 days, imipenem-cilastatin 500 mg IV q 6 h for 5 daysCulture on third day showed ESBL +ve sensitive only to carbapenem.Suspected complicated pyelonephritisImipenem-cilastatin 250 mg IV q 12 h for 5 daysA history of nephrolithiasis underwent left nephrectomy at 2 years old, patient had multiple admissions for recurrent UTI, should be treated with IV ABX.ESBL negative UTI, complicated pyelonephritisImipenem/cilastatin 500 mg IV q6hours for 3 daysCulture sensitive to only IV ABX, and the patient on second day had a spike of feverDiabetic foot infectionImipenem/cilastatin 500 mg IV q 6 h for 6 daysDiabetic foot ulcer with pus sensitive only to IV ABXESBL + UTI, complicated cystitisImipenem/cilastatin 250 mg IV q 6 h for 6 daysESBL +ve should be treated with IV carbapenemDiabetic foot infectionImipenem/cilastatin 500 mg IV q 6 h for 2 daysModerate to severe infection require IV ABXESBL + UTI, complicated cystitisImipenem/cilastatin 500 mg IV q 6 h for 6 daysESBL +ve should be treated with IV carbapenem.ESBL + UTI, complicated cystitisImipenem/cilastatin500 mg IV q 6 h for 6 daysESBL +ve should be treated with IV carbapenem.Wound infection, right groin wound infection post varicose vein stripping surgeryPiperacillin/tazobactam 4.5 g IV q 6 h for 8 daysHigh WBC at admission, 16000, however sever infection cannot be converted to oral ABXSuspected complicated pyelonephritisCeftriaxone 2 g IV once daily for 6 daysPatient had multiple episode of vomiting, elevated WBC 12Infected DM foot in left second toe, had ulceration, for amputation, culture showed ESBL +veMeropenem 1 g IV q 8 h, metronidazole 500 mg IV q 8 h for 6 daysESBL +ve culture of diabetic foot infection need IV ABX.Patient had chronic cough, pulmonary edema, admitted as Pulmonary embolism vs chest infectionLevofloxacin 250 mg IV once daily for 12 daysPatient clinically deteriorated and was put on JET nebulizer and migrated to ICUAspiration pneumonia, patient had history of chocking and difficulty swallowing, and decrease oral intakePiperacillin/tazobactam 4.5 g IV q 6 h for 5 days, imipenem/cilastatin 500 mg IV twice daily for 10 days, meropenem500 mg IV three times daily for 10 days, levofloxacin 500 mg IV once daily for 7 daysPatient was clinically deteriorated and had difficulty swallowingComplicated cystitis, ESBL + UTICeftriaxone 2 g IV once daily for 3 daysCulture result on third day was ESBL +ve UTI, should be treated with IV carbapenem, but patient dischargedBilateral foot ulcer, patient had DMPiperacillin/tazobactam 4.5 g IV q 6 h, metronidazole 500 mg IV q 8 h for 4 daysSever infectionCellulitis and infected wound in left legPiperacillin/tazobactam 4.5 g IV q 6 h, metronidazole 500 mg IV q 8 h for 10 daysSever infectionESBL + UTI, complicated cystitisImipenem/cilastatin 500 mg IV q 6 h for 6 daysESBL +veUTI, should be treated with IV carbapenemESBL + UTI, complicated cystitisImipenem/cilastatin500 mg IV q 6 h for 4 daysESBL +veUTI, should be treated with IV carbapenemComplicated cystitis P. aeruginosa, stone former, history of urethral implantationCeftriaxone 2 g IV once daily for 4 daysAs the patient had history of urethral implantation, stone former, on third day of admission UC showed P. aeruginosa sensitive only for IV ABXPneumonia diagnosed by imagingPiperacillin/tazobactam 4.5 g IV q 6 h for 7 days, vancomycin 1 g IV once daily for 5 days, ceftriaxone 1 g IV q 12 h for 5 daysPatient was clinically unstable, and developed spikes of fever during admissionESBL + UTI, complicated pyelonephritisImipenem/cilastatin 500 mg IV q 6 h for 7 daysESBL +veUTI, should be treated with IV carbapenem.Suspected complicated pyelonephritisErtapenem 0.5 g IV once daily for 4 daysPatient had previous admission before 3 days with same complaint and had ESBL +ve UTI sensitive to IV ertapenemPregnant with peritonsillar abscess, penicillin allergyMetronidazole 500 mg q 8 h, ceftriaxone 1 g q 12 h for 4 daysPatient had difficulty swallowing cannot be converted to oral ABXESBL +ve complicated cystitisImipenem/cilastatin 500 mg IV q 6 h for 5 daysESBL +veUTI, should be treated with IV carbapenem[^3]

4. Discussion {#s0050}
=============

The current study evaluates the appropriateness of antibiotic prescription and the implementation of IV to PO conversion guidelines in one of the largest hospitals in Jordan. The study findings reveal that a relatively high percentage (47.5%) of the patients were on IV antibiotics although they were eligible for IV to PO conversion. Approximately, one third (32.43%) of the patients who had urinary tract infections were not prescribed the appropriate antibiotics and 36.25% of the patients were prescribed antibiotics without renal dose adjustments. Such findings clearly demonstrate the lack of the implementation of guidelines for antibiotics use and highlight the need for clinical pharmacists' involvement in antibiotics prescription for patients with different infectious diseases.

The CDC estimated that around 30% of antibiotics use in hospitals is inappropriate or unnecessary, and this will impede the achievement of desired outcomes and will expose the patients to the risk of adverse events including C. difficile infections and developing of antibiotic resistant infections ([@b0040]). The application of ASP guidelines regarding the avoidance of antibiotics when appropriate or when they are indicated, and the use of appropriate selection and dose regimen, will increase clinical cure rates and decrease the toxicity and resistance ([@b0005]).

The implementation of IV to PO conversion leads to a significant reduction in the length of hospital stay and the total duration of antibiotic therapy, in addition to catheter-related infections ([@b0035]). It has been approved that antibiotics with high bioavailability such as fluoroquinolones, both the IV and the oral routes resulted in similar cure rates ([@b0060]). Consistent with the current study findings, Ahkee et al. reported that 46% of the inpatients were treated with IV antibiotics although they were candidate for switch to oral therapy ([@b0010]). According to a study conducted on patients with community acquired pneumonia who were given moxifloxacin, the conversion to oral antibiotics led to a decrease in antibiotics cost and an increase in the rate of success of clinical treatment ([@b0030]). Another study regarding inpatients with community acquired pneumonia found that early switch from IV to oral third generation cephalosporine was clinically effective and reduced the hospital stay effectively ([@b0075]).

Our study is the first study in Jordan that determines the adherence of IV to PO conversion rules. In summary, there is an urgent need to improve the clinical practice with regard to antibiotics use and administration via assuring the correct indication, doses and route of administration, identifying patients who are candidate for switching to oral antibiotics in the appropriate time, and adjusting doses based on clinical characteristics of the patients. The optimal implementation of such duties requires the involvement of clinical pharmacist who is expert in infectious diseases scope. Furthermore, there is a need for periodic educational programs for healthcare professionals about antibiotics and their resistance and guidelines for optimal treatment of different infections.

Study limitations {#s0055}
-----------------

The small sample size represents a major limitation of the current study and increasing the sample size could help withdrawing more robust conclusions from the current study. Furthermore, the study was not conducted in multiple centers which could limit the generalizability of the current study findings.

5. Conclusion {#s0060}
=============

This study shows a shortage in the implementation of guidelines that are necessary to decrease antibiotics resistance and improving clinical outcomes. Clinical pharmacists should have a better understanding of antibiotics use and prescription guidelines in addition to improved awareness of antibiotics resistance concept. They should be more involved in antibiotics prescription practice with the aim of improving effectiveness and decreasing potential antimicrobial resistance in hospital settings. Future successful clinical pharmacy service programs should emphasize on the provision of optimal antibiotic therapy in order to improve health outcomes among hospitalized patients with different infectious diseases. Future research is needed to be implemented on patients with infections not investigated in the current study. Other studies are also needed to evaluate the clinical and economic impact of implementing ASP on hospitalized patients with different infections.
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[^1]: CrCl: reatinine clearence.

[^2]: UA: urine analysis, ABX: antibiotic, UC: urine culture, WBC: white blood cell, ESBL: extended spectrum beta lactamase, UTI: Urinary tract infection, SOB: shortness of breath, HF: heart failure, PTA: prior to admission, COPD: chronic obstructive pulmonary disease, CABG: coronary artery bypass graft, MRSA: methicillin-resistant staph aureus.

[^3]: MDR: multi-drug resistance, UTI: Urinary tract infection, ESBL: extended spectrum beta lactamase, UC: urine culture, TB: tuberculosis, ABX: antibiotic, WBC: white blood cell count, DM: diabetes mellitus, ICU: intensive care unit.
